Five Prime Therapeutics provided an update on the development of bemarituzumab and FPA150, and Gritstone Oncology discussed plans for its personalized immunotherapies.
Olaparib is the first PARP inhibitor approved in China for first-line maintenance treatment of germline and somatic BRCA mutated gynecological cancers.
The guidelines place a stronger emphasis on pancreatic cancer risk genes, and broaden testing recommendations for those with Ashkenazi Jewish ancestry.
For heavily pretreated ovarian cancer patients, doctors will now have to weigh their HRD status in the context of an increasingly complex backdrop of biomarker information.
The drug is now approved as a fourth-line option for advanced, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency.
Data from more than 11,800 women with breast cancer suggested unselected BRCA1, BRCA2, and PALB2 testing is cost-effective for UK and US payors and societies.
Findings from three Phase III clinical trials suggest that PARP inhibitors may prolong disease-free survival in some advanced ovarian cancer patients without BRCA1/2 mutations.
The data showed that population screening for BRCA mutations in Ashkenazi Jewish population doesn't diminish quality of life or cause psychological distress.
